Keyword: Samsung BioLogics

India scrutinizes whistleblower case against Sun; FDA slaps warning letter on valsartan API maker; Eisai and UCL push anti-tau drug into the clinic.

A Chinese researcher claims is the world's first gene-edited babies; Takeda's Shire deal faces last-minute drama; Celltrion wins first Rituxan biosim nod.

Samsung is fighting back against charges that it improperly changed the method by which it valued a joint venture with Biogen.

Samsung BioLogics faces potential delisting; Merck will increase Gardasil supply to China; Chinese officials mulls new regulation for vaccine.

Korean securities watchdog has requested to review whether the company should be delisted and recommended the dismissal of its CEO.

Here is some other pharma manufacturing news of note for the week.

Former China FDA chief resigns over vaccine scandal; Astellas buys gene therapy specialist Quethera; FDA found problems at valsartan maker Huahai.

Lenvima's quarterly sales grow to $106 million; China makes 48-drug list for streamlined review; Samsung commits further investment in biologics.

Samsung BioLogics is slated to get a piece of the $22 billion investment Samsung says it will invest in growth businesses.

Eisai and Biogen's recent Alzheimer's data spark debate; Beijing works to contain a vaccine scandal; BMS and Tsinghua University pen drug discovery pact.